Pharma BD Deal Intelligence
Bayer acquired AskBio for $2B for investigational gene therapy compounds.
Bayer to buy AskBio for $2B to become a gene therapy player gaining AAV platform for Pompe and Parkinson.
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Bayer acquired AskBio for $2B for investigational gene therapy compounds.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / Asklepios BioPharmaceuticals (this deal) | 2020 | $2.0B | 49 |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Schering AG (residual squeeze-out) | 2007 | $985M | 69 |
| Bayer AG / Arvinas, Inc. | 2019 | $1.0B | 59 |
| Bayer AG / Merck & Co. Inc. | 2014 | $14.2B | 56 |
← Browse all deals · How we score deals
More: 2020 deals · Bayer AG deals · Cardiovascular deals